Literature DB >> 28306507

Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells.

Joshua D Stender1, Jerome C Nwachukwu2, Irida Kastrati3, Yohan Kim4, Tobias Strid1, Maayan Yakir1, Sathish Srinivasan2, Jason Nowak2, Tina Izard2, Erumbi S Rangarajan2, Kathryn E Carlson5, John A Katzenellenbogen5, Xin-Qiu Yao6, Barry J Grant6, Hon S Leong7, Chin-Yo Lin8, Jonna Frasor3, Kendall W Nettles2, Christopher K Glass9.   

Abstract

Human breast cancers that exhibit high proportions of immune cells and elevated levels of pro-inflammatory cytokines predict poor prognosis. Here, we demonstrate that treatment of human MCF-7 breast cancer cells with pro-inflammatory cytokines results in ERα-dependent activation of gene expression and proliferation, in the absence of ligand or presence of 4OH-tamoxifen (TOT). Cytokine activation of ERα and endocrine resistance is dependent on phosphorylation of ERα at S305 in the hinge domain. Phosphorylation of S305 by IKKβ establishes an ERα cistrome that substantially overlaps with the estradiol (E2)-dependent ERα cistrome. Structural analyses suggest that S305-P forms a charge-linked bridge with the C-terminal F domain of ERα that enables inter-domain communication and constitutive activity from the N-terminal coactivator-binding site, revealing the structural basis of endocrine resistance. ERα therefore functions as a transcriptional effector of cytokine-induced IKKβ signaling, suggesting a mechanism through which the tumor microenvironment controls tumor progression and endocrine resistance.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  breast cancer; crystallography; cytokines; drug resistance; estrogen receptor; inflammation; tamoxifen

Mesh:

Substances:

Year:  2017        PMID: 28306507      PMCID: PMC5546241          DOI: 10.1016/j.molcel.2017.02.008

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  76 in total

1.  Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation.

Authors:  Araz Jakalian; David B Jack; Christopher I Bayly
Journal:  J Comput Chem       Date:  2002-12       Impact factor: 3.376

Review 2.  Crosstalk in NF-κB signaling pathways.

Authors:  Andrea Oeckinghaus; Matthew S Hayden; Sankar Ghosh
Journal:  Nat Immunol       Date:  2011-07-19       Impact factor: 25.606

3.  Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivity.

Authors:  Robert W Hsieh; Shyamala S Rajan; Sanjay K Sharma; Yuee Guo; Eugene R DeSombre; Milan Mrksich; Geoffrey L Greene
Journal:  J Biol Chem       Date:  2006-04-28       Impact factor: 5.157

4.  Synergism between ERalpha transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: requirement for the AF-1 alpha-helical core and for a direct interaction between the N- and C-terminal domains.

Authors:  R Métivier; G Penot; G Flouriot; F Pakdel
Journal:  Mol Endocrinol       Date:  2001-11

5.  CBP mediates NF-κB-dependent histone acetylation and estrogen receptor recruitment to an estrogen response element in the BIRC3 promoter.

Authors:  Madhumita Pradhan; Sarah C Baumgarten; Leslie A Bembinster; Jonna Frasor
Journal:  Mol Cell Biol       Date:  2011-11-14       Impact factor: 4.272

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

8.  NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen.

Authors:  L A deGraffenried; B Chandrasekar; W E Friedrichs; E Donzis; J Silva; M Hidalgo; J W Freeman; G R Weiss
Journal:  Ann Oncol       Date:  2004-06       Impact factor: 32.976

9.  Estrogen receptor activation function 1 works by binding p160 coactivator proteins.

Authors:  P Webb; P Nguyen; J Shinsako; C Anderson; W Feng; M P Nguyen; D Chen; S M Huang; S Subramanian; E McKinerney; B S Katzenellenbogen; M R Stallcup; P J Kushner
Journal:  Mol Endocrinol       Date:  1998-10

10.  Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription.

Authors:  Minna U Kaikkonen; Nathanael J Spann; Sven Heinz; Casey E Romanoski; Karmel A Allison; Joshua D Stender; Hyun B Chun; David F Tough; Rab K Prinjha; Christopher Benner; Christopher K Glass
Journal:  Mol Cell       Date:  2013-08-08       Impact factor: 17.970

View more
  38 in total

1.  BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes.

Authors:  Hiroyuki Sasanuma; Masataka Tsuda; Suguru Morimoto; Liton Kumar Saha; Md Maminur Rahman; Yusuke Kiyooka; Haruna Fujiike; Andrew D Cherniack; Junji Itou; Elsa Callen Moreu; Masakazu Toi; Shinichiro Nakada; Hisashi Tanaka; Ken Tsutsui; Shintaro Yamada; Andre Nussenzweig; Shunichi Takeda
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-23       Impact factor: 11.205

2.  USP22 positively modulates ERα action via its deubiquitinase activity in breast cancer.

Authors:  Shengli Wang; Xinping Zhong; Chunyu Wang; Hao Luo; Lin Lin; Hongmiao Sun; Ge Sun; Kai Zeng; Renlong Zou; Wei Liu; Ning Sun; Huijuan Song; Wensu Liu; Qiang Zhang; Zhixuan Liao; Xiaochun Teng; Tingting Zhou; Xun Sun; Yue Zhao
Journal:  Cell Death Differ       Date:  2020-06-03       Impact factor: 15.828

3.  BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells.

Authors:  Shyam Nathan; Yongxian Ma; York A Tomita; Eliseu De Oliveira; Milton L Brown; Eliot M Rosen
Journal:  Breast Cancer Res Treat       Date:  2017-08-14       Impact factor: 4.872

4.  c-Jun/AP-1 overexpression reprograms ERα signaling related to tamoxifen response in ERα-positive breast cancer.

Authors:  Huan He; Indranil Sinha; Rongrong Fan; Lars-Arne Haldosen; Feifei Yan; Chunyan Zhao; Karin Dahlman-Wright
Journal:  Oncogene       Date:  2018-02-22       Impact factor: 9.867

5.  Coactivation of Estrogen Receptor and IKKβ Induces a Dormant Metastatic Phenotype in ER-Positive Breast Cancer.

Authors:  Lamiaa El-Shennawy; Oleksii Dubrovskyi; Irida Kastrati; Jeanne M Danes; Yiqun Zhang; Herbert E Whiteley; Chad J Creighton; Jonna Frasor
Journal:  Cancer Res       Date:  2017-12-11       Impact factor: 12.701

6.  The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.

Authors:  Irida Kastrati; Stacey E P Joosten; Svetlana E Semina; Luis H Alejo; Svitlana D Brovkovych; Joshua D Stender; Hugo M Horlings; Marleen Kok; Elaine T Alarid; Geoffrey L Greene; Sabine C Linn; Wilbert Zwart; Jonna Frasor
Journal:  Mol Cancer Res       Date:  2020-04-03       Impact factor: 5.852

7.  TLR4 activation leads to anti-EGFR therapy resistance in head and neck squamous cell carcinoma.

Authors:  Houyu Ju; Zhenrong Hu; Yusheng Lu; Yunteng Wu; Liming Zhang; Dongliang Wei; Wei Guo; Weiya Xia; Shuli Liu; Guoxin Ren; Jingzhou Hu
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

Review 8.  Chromatin reprogramming in breast cancer.

Authors:  Erin E Swinstead; Ville Paakinaho; Gordon L Hager
Journal:  Endocr Relat Cancer       Date:  2018-04-24       Impact factor: 5.678

9.  ESR1-Stabilizing Long Noncoding RNA TMPO-AS1 Promotes Hormone-Refractory Breast Cancer Progression.

Authors:  Yuichi Mitobe; Kazuhiro Ikeda; Takashi Suzuki; Kiyoshi Takagi; Hidetaka Kawabata; Kuniko Horie-Inoue; Satoshi Inoue
Journal:  Mol Cell Biol       Date:  2019-11-12       Impact factor: 4.272

Review 10.  Update on the Role of NFκB in Promoting Aggressive Phenotypes of Estrogen Receptor-Positive Breast Cancer.

Authors:  Emily Smart; Svetlana E Semina; Jonna Frasor
Journal:  Endocrinology       Date:  2020-10-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.